文献速递类风湿关节炎

乌帕替尼治疗类风湿关节炎患者带状疱疹发生率与危险因素:六项III期临床试验汇总分析

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
PubMed 文献 · Ann Rheum Dis · 2021-10-06

该汇总分析基于六项III期随机试验,评估乌帕替尼(UPA)治疗类风湿关节炎(RA)患者带状疱疹(HZ)的发生率与危险因素。结果显示UPA 15mg和30mg组HZ发生率分别为3.0和5.3/100患者年,高于甲氨蝶呤单药(0.8)和阿达木单抗+甲氨蝶呤(1.1);既往HZ史和亚洲地区是UPA治疗患者的HZ危险因素。

要点

  • UPA 30mg组HZ发生率(5.3/100患者年)高于15mg组(3.0/100患者年)。
  • UPA组HZ发生率高于ADA+MTX或MTX单药组。
  • 既往HZ史和亚洲地区是UPA治疗患者HZ的危险因素。

核心结论

  • 在UPA III期RA临床项目中,UPA组HZ发生率和事件率高于ADA+MTX或MTX单药组,且30mg剂量高于15mg剂量。
  • 亚洲患者和既往有HZ史的患者在接受UPA治疗时HZ风险可能增加。

研究设计与样本

  • 汇总分析六项随机III期临床试验,数据截止2020年6月30日,共纳入5306例患者。
  • 计算UPA(单药或联合)及MTX单药、ADA+MTX组HZ的暴露调整发生率/事件率。
  • 采用多变量Cox回归分析识别UPA治疗患者中HZ的危险因素。

主要发现

  • HZ发生率/100患者年(95%CI):MTX单药组0.8(0.3-1.9),ADA+MTX组1.1(0.5-1.9),UPA 15mg组3.0(2.6-3.5),UPA 30mg组5.3(4.5-6.2)。
  • UPA治疗患者中 majority(71%)HZ病例累及单一皮节。
  • UPA治疗患者中HZ的危险因素包括既往HZ史和亚洲地区。

关键数值与推荐

  • HZ发生率/100患者年(95%CI):MTX单药0.8(0.3-1.9),ADA+MTX 1.1(0.5-1.9),UPA 15mg 3.0(2.6-3.5),UPA 30mg 5.3(4.5-6.2)。
  • UPA组71%的HZ病例累及单一皮节。
  • UPA治疗患者HZ危险因素:既往HZ史和亚洲地区。

临床怎么用

  • 对接受UPA治疗的RA患者,尤其来自亚洲或有HZ病史者,应警惕HZ风险。
  • UPA 30mg剂量下HZ发生率高于15mg,临床决策时需权衡剂量相关风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis (RA). JAK inhibitors have been associated with an increased risk of herpes zoster (HZ) in patients with RA. OBJECTIVES: To evaluate the incidence and risk factors for HZ in UPA-treated patients with RA from the UPA phase III clinical trial programme. METHODS: Exposure-adjusted incidence/event rates for HZ were determined in patients receiving UPA (monotherapy or combination therapy) in six randomised phase III trials (data cut-off on 30 June 2020). HZ incidence and event rates were also determined in patients receiving methotrexate (MTX) monotherapy or adalimumab (ADA) + MTX. Multivariable Cox regression analysis was used to identify HZ risk factors in UPA-treated patients. RESULTS: A total of 5306 patients were included in this analysis. The incidence rate of HZ/100 patient-years (95% CI) was 0.8 (0.3 to 1.9), 1.1 (0.5 to 1.9), 3.0 (2.6 to 3.5) and 5.3 (4.5 to 6.2), in the MTX monotherapy, ADA + MTX, UPA 15 mg and UPA 30 mg groups, respectively. The majority of HZ cases with UPA (71%) involved a single dermatome. Prior history of HZ and Asian region were HZ risk factors in UPA-treated patients. CONCLUSION: In the UPA phase III RA clinical programme, HZ incidence and event rates were higher with UPA versus ADA + MTX or MTX monotherapy, and higher with the 30 mg versus 15 mg dose. Patients from Asia and those with a history of HZ may be at increased risk of HZ while receiving UPA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Winthrop KL, Nash P, Yamaoka K, et al. Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Ann Rheum Dis. 2021. PMID: 34615638. doi:10.1136/annrheumdis-2021-220822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。